On October 8, from 09:00 to 10:00, the first Russian body public talk "Body, weight, figure – challenges in the fight for beauty and health" will take place in the small hall of the Gelendzhik Arena. GEROPHARM, a national manufacturer of biotechnological drugs, has developed a unique discussion format to draw attention to the problem of overweight and obesity in Russia.
What is beauty now and how its standards have changed over the centuries will be discussed by representatives of the medical community, the media, the arts and pharma.
The star guest of body public talk will be singer and actress Anna Semenovich, the ambassador of healthy weight loss. After retiring from professional sports, Anna began to have problems with metabolic processes, which led to insulin resistance. That's when it came to understanding that being overweight is not about reflection in the mirror, but, first of all, about health.
Now Anna Semenovich is on the path of healthy weight loss and wants to share her story with as many people as possible. In the era of social media, it is important to show not the perfect picture, but the truth – what kind of work, mental and physical, is behind beautiful photos. The audience of body public talk will receive a lecture "The History of female beauty: from Venus to Bella Hadid", doctors' view of obesity in the 21st century, an honest conversation about the wonders of pharma and the role of the media in the fight for slimness.
Speakers:
·Oksana Drapkina, Director, NMIC TPM of the Ministry of Health of the Russian Federation, Chief Freelance Specialist in therapy and General Medical Practice of the Ministry of Health of the Russian Federation
·Anna Semenovich, singer and actress
·Marina Rykova, Editor-in-chief of the portal stroynee.pro
·Roman Dry, Director of the GEROPHARM R&D Center
Moderator:
Roman Gerasimov – Head of information projects at RBC Petersburg, journalist, TV presenter
In 2023, GEROPHARM registered Semavik®, the first Russian analogue of Ozempik®, which has ceased to be supplied to Russia. The active substance Semavik® – semaglutide – is an agonist of GPP-1 receptors (GPP-1P) produced by chemical synthesis. Semaglutide reduces total body weight and adipose tissue mass, reducing energy consumption.
What is beauty now and how its standards have changed over the centuries will be discussed by representatives of the medical community, the media, the arts and pharma.
The star guest of body public talk will be singer and actress Anna Semenovich, the ambassador of healthy weight loss. After retiring from professional sports, Anna began to have problems with metabolic processes, which led to insulin resistance. That's when it came to understanding that being overweight is not about reflection in the mirror, but, first of all, about health.
Now Anna Semenovich is on the path of healthy weight loss and wants to share her story with as many people as possible. In the era of social media, it is important to show not the perfect picture, but the truth – what kind of work, mental and physical, is behind beautiful photos. The audience of body public talk will receive a lecture "The History of female beauty: from Venus to Bella Hadid", doctors' view of obesity in the 21st century, an honest conversation about the wonders of pharma and the role of the media in the fight for slimness.
Speakers:
·Oksana Drapkina, Director, NMIC TPM of the Ministry of Health of the Russian Federation, Chief Freelance Specialist in therapy and General Medical Practice of the Ministry of Health of the Russian Federation
·Anna Semenovich, singer and actress
·Marina Rykova, Editor-in-chief of the portal stroynee.pro
·Roman Dry, Director of the GEROPHARM R&D Center
Moderator:
Roman Gerasimov – Head of information projects at RBC Petersburg, journalist, TV presenter
In 2023, GEROPHARM registered Semavik®, the first Russian analogue of Ozempik®, which has ceased to be supplied to Russia. The active substance Semavik® – semaglutide – is an agonist of GPP-1 receptors (GPP-1P) produced by chemical synthesis. Semaglutide reduces total body weight and adipose tissue mass, reducing energy consumption.